“Bruce had a brilliant career in both academia and industry and left an indelible mark on the Alzheimer’s disease drug development landscape,” noted Robert Vassar, Northwestern University, Chicago ...

The North American vision care products and services market is projected to grow significantly, with an estimated valuation of USD 65,326.3 million in 2023. By 2033, the market is expected to reach ...

Big pharmaceutical companies including the two big Swiss players, Roche and Novartis, had a lot at stake in the US ...

The global ophthalmic lasers market is estimated to be valued at USD 976.8 million in 2024 and is expected to experience ...

In April 2021, Novartis AG announced a collaboration with Artios Pharma. This collaboration was made to improve both companies’ discovery platforms, leverage their knowledge, and improve the potential ...

Roche may delay launch Alnylam pauses study Relay delays launch Seagen cancels study Bristol Myers discontinues study Novartis delays launch Drugmakers are “openly saying ‘We have this product that ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

Siponimod, branded by Swiss-drug major Novartis as Mayzent, is reportedly the first oral treatment indicated for active SPMS in adults. Novartis, while announcing its FDA approval for Mayzent in 2019, ...

The global diabetic macular edema market is on a steady growth trajectory, with an expected valuation of approximately USD 4,120.9 million in 2024. The market is poised to surpass USD 4,642.9 million ...

With an array of new medicines and medical devices on display, global medical companies are looking to tap further into the ...

Executed global exclusive development and commercialization license agreement with Novartis to advance VAV1-directed molecular glue degraders including MRT-6160 for immune-related conditions; $150M ...